Personalis, INC 8-K filings

Personalis, Inc. announced a definitive agreement to merge with Tempus AI, Inc. in a stock-for-stock transaction, with specific terms regarding stock consideration and potential cash payouts.

Tempus AI announces definitive agreement to acquire Personalis for $1.5 billion, aiming to integrate Personalis's MRD technology into its AI-enabled precision oncology platform.

Personalis, Inc. announced expanded Medicare coverage for its NeXT Personal test, now including monitoring treatment response for specific breast cancer types.

Personalis, Inc. stockholders successfully elected directors, ratified auditors, and approved executive compensation at the 2026 annual meeting.

Personalis, Inc. announced expanded Medicare coverage for its NeXT Personal test, now including immunotherapy monitoring for late-stage solid tumors.

Personalis, Inc. announced the appointment of Richard Chen as its new President, effective March 13, 2026, alongside an increase in his compensation and new equity awards.

Personalis, Inc. announced a significant surge in clinical test volume and pivotal Medicare coverage approvals for breast and lung cancer surveillance, alongside robust 2026 revenue guidance.

Personalis, Inc. announced preliminary Q4 and full-year 2025 results, highlighting a significant surge in clinical test volume and pivotal Medicare coverage for breast cancer surveillance.

Personalis, Inc. filed a prospectus supplement for an at-the-market offering to sell up to $100 million of its common stock.

Personalis, Inc. announced revised Medicare reimbursement rates for its NeXT Personal cancer recurrence monitoring tests, effective December 1, 2025.

Personalis's ultrasensitive NeXT Personal test has secured Medicare coverage for post-treatment surveillance of stage II and III breast cancer recurrence.

Personalis, Inc. reported a 44% year-over-year revenue decrease in Q3 2025 to $14.5 million, driven by expected declines, but saw a 364% surge in clinical test volume for its NeXT Personal platform.

Personalis, Inc. announced a new task order worth up to $13.5 million under its contract with the U.S. Department of Veterans Affairs Million Veteran Program, increasing the cumulative contract value to approximately $225.0 million.

Personalis, Inc. reported a 24% year-over-year revenue decline in Q2 2025 and lowered its full-year revenue guidance, despite strong clinical test volume growth.

Personalis, Inc. announced an amendment to its agreement with Tempus AI, extending their partnership through 2029 and adding colorectal cancer as a new indication for its NeXT Personal minimal residual disease test, alongside an extended exclusivity period.

Personalis, Inc. successfully held its 2025 annual meeting, with stockholders electing directors, ratifying the auditor, and approving executive compensation.

Personalis, Inc. announced a 6% increase in revenue for Q1 2025, driven by a 39% surge in pharma tests and services revenue and a 52% increase in clinical test volume.

Personalis, Inc. announces its fourth quarter and full year 2024 financial results, highlighting a 15% increase in full-year revenue and a strategic investment from Merck.

Personalis, Inc. announced preliminary full-year 2024 revenue of approximately $84.6 million, a 15% increase year-over-year, exceeding their previous guidance.

Personalis, Inc. has amended its at-the-market sales agreement to include Piper Sandler & Co. as a sales agent, allowing the company to offer and sell shares of its common stock.

Personalis, Inc. has entered into a $50 million investment agreement with Merck Sharp & Dohme LLC, involving the sale of common stock and strategic collaborations.

Personalis, Inc. announced a 41% year-over-year revenue increase in Q3 2024, driven by a 96% surge in biopharma revenue, and raised its full-year revenue guidance.

Personalis, Inc. has been awarded a new task order worth up to $7.5 million under its contract with the U.S. Department of Veterans Affairs' Million Veteran Program.

Personalis, Inc. has secured a $36 million investment from Tempus AI through a share purchase and warrant exercise, while also expanding their commercial partnership.

Personalis, Inc. announced a 35% year-over-year revenue increase in the second quarter of 2024, driven by a 117% surge in biopharma revenue, and raised its full-year revenue guidance.

Personalis and Foresight Diagnostics have entered into a settlement and license agreement, resolving ongoing patent litigation and inter-partes review proceedings.

Personalis, Inc. held its 2024 annual meeting, electing three directors, ratifying its auditor, and approving executive compensation on an advisory basis.

Personalis reported strong first-quarter 2024 results, exceeding revenue expectations and raising its full-year revenue guidance due to increased demand for pharma testing.

Personalis, Inc. announced an 18% increase in fourth-quarter revenue and key strategic partnerships, while also providing its financial outlook for 2024.